Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside

Core Insights - Travere Therapeutics, Inc. (NASDAQ:TVTX) reached an all-time high on Wednesday following the FDA's decision to cancel the creation of an advisory committee for its drug application to treat focal segmental glomerulosclerosis (FSGS) [1][3] - The stock price peaked at $28.69 during the session, ultimately closing up 26.2% at $27.31 [2] - The FDA's decision indicates reduced concerns regarding the drug candidate, Filspari, which aims to be the first treatment for FSGS, a major cause of kidney failure [3] Company Developments - Travere Therapeutics is optimistic about the progress of its supplemental New Drug Application (sNDA) for Filspari and is preparing for a commercial launch expected by January 2026 [4] - Filspari is characterized as an oral, non-immunosuppressive therapy targeting podocyte injury, a significant factor in the progression of FSGS [4] - The CEO of Travere Therapeutics emphasized the urgent need for approved therapies for FSGS, highlighting the long wait patients have endured for treatment options [5]